Retosiban
- Generic Name
- Retosiban
- Drug Type
- Small Molecule
- Chemical Formula
- C27H34N4O5
- CAS Number
- 820957-38-8
- Unique Ingredient Identifier
- GIE06H28OX
- Background
Retosiban has been used in trials studying the treatment of Premature Labor and Obstetric Labour, Premature.
Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women
Phase 1
Completed
- Conditions
- Obstetric Labour, Premature
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT02377414
- Locations
- πΊπΈ
GSK Investigational Site, Glendale, California, United States
A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor
Phase 3
Terminated
- Conditions
- Obstetric Labour, Premature
- Interventions
- Drug: Placebo IV infusion
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT02377466
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies
Phase 3
Completed
- Conditions
- Obstetric Labour, Premature
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 98
- Registration Number
- NCT02292784
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour
Phase 3
Terminated
- Conditions
- Obstetric Labour, Premature
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT02292771
- Locations
- π¬π§
GSK Investigational Site, Sheffield, United Kingdom
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT01867996
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.
Phase 1
Completed
- Conditions
- Obstetric Labour, Premature
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT01702376
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
Absorption, Distribution, Metabolism And Excretion Study For GSK221149A
Phase 1
Completed
- Conditions
- Obstetric Labour, PrematurePremature Labor
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT00457925
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 93
- Registration Number
- NCT00404768
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath